Assessing breast cancer risk

References

• Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54(1): 8–29
   PubMed Web of Science ®Google Scholar
• Mincey BA. Genetics and the management of women at high risk for breast cancer. Oncologist 2003; 8(5): 466–73
   Google Scholar
• Narod SA, Ford D, Devilee P, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56(1): 254–64
   Google Scholar
• Cancer risks in BRCA2 mutation carriers. Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999; 91(15): 1310–6
   Google Scholar
• Liede A, Karian BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004; 22(4): 735–42
   PubMed Web of Science ®Google Scholar
• Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCAI mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94(18): 1365–72
   PubMedGoogle Scholar
• Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998; 90(14): 1039–71
   PubMedGoogle Scholar
• Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119(6): 1447–53
   PubMed Web of Science ®Google Scholar
• Vogel VG. Management of the high-risk patient. Surg Clin North Am 2003; 83(4): 733–51
   Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321–33
   PubMed Web of Science ®Google Scholar
• Page DL, Jensen RA, Simpson JF, et al. Historical and epidemiologic background of human premalignant breast disease. J Mammary Gland Biol Neoplasia 2000; 5(4): 341–9
   Google Scholar
• Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004; 230(1): 29–41
   Google Scholar
• McTiernan A. Behavioral risk factors in breast cancer: Can risk be modified? Oncologist 2003; 8(4): 326–34
   PubMed Web of Science ®Google Scholar
• Lee IM. Physical activity and cancer prevention—data from epidemiologic studies. Med Sci Sports Exerc 2003; 35(11): 1823–7
   PubMed Web of Science ®Google Scholar
• Hamajima N, Hirase K, Tajima K, et al; Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer—collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002; 87(11): 1234–45
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat databases: incidence—SEER 11 regs + Alaska public-use, Nov 2003 sub for expanded races (1992–2001). National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch. Available at: http://www.seer.cancer.gov. Accessed Jul 20, 2004
   Google Scholar
• Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94(8): 606–16
   PubMed Web of Science ®Google Scholar
• Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346(26): 2025–32
   PubMed Web of Science ®Google Scholar
• Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996; 347(9017): 1713–27
   PubMed Web of Science ®Google Scholar
• Horwich A, Swerdlow AJ. Second primary breast cancer after Hodgkin's disease. Br J Cancer 2004; 90(2): 294–8
   Google Scholar
• Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81(24): 1879–86
   PubMed Web of Science ®Google Scholar
• Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer 1994; 73(3): 643–51
   PubMed Web of Science ®Google Scholar
• Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 1993; 28(2): 115–20
   Google Scholar
• Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999; 91(18): 1541–8
   PubMed Web of Science ®Google Scholar
• Domchek SM, Eisen A, Calzone K, et al. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 2003; 21(4): 593–601
   Google Scholar
• National Comprehensive Cancer Network. Breast cancer screening and diagnosis guidelines. NCCN clinical practice guidelines in oncology, version 1.2003. Jenkintown, Pa: National Comprehensive Cancer Network, 2003
   Google Scholar
• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNatl Cancer Inst 1998; 90(18): 1371–88
   PubMed Web of Science ®Google Scholar
• Serrano D, Perego E, Costa A, et al. Progress in chemoprevention of breast cancer. Crit Rev Oncol Hematol 2004; 49(2): 109–17
   Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282(7): 637–45 [Erratum, JAMA 1999; 282(22): 2124]
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA, et al. The effects of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999; 281(23): 2189–97 [Erratum, JAMA 1999; 282(22): 2124]
   PubMed Web of Science ®Google Scholar
• National Surgical Adjuvant Breast and Bowel Project. End in sight for first phase of major breast cancer prevention study. Pittsburgh: NSABP, Mar 4, 2004
   Google Scholar
• Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22(6): 1055–62
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Lynch HT, Neuhausen SL, et al; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346(21): 1616–22
   PubMed Web of Science ®Google Scholar
• Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346(21): 1609–15
   PubMed Web of Science ®Google Scholar
• Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351(5): 427–37
   PubMed Web of Science ®Google Scholar
• Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001; 19(15): 3524–31
   Google Scholar